Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/12/25
End: 03/23/25
Due: 03/23/26
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
Phase: N/A
Priority: Normal
Start: 11/20/23
End: 03/30/25
Due: 03/30/26
Phase: N/A
Priority: Normal
Start: 05/19/23
End: 05/02/24
Due: 05/02/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate Metabolism, Excretion, and Mass Balance of [14C]Vapendavir | NCT06834295 | Altesa Biosciences, Inc. | user2@example.com | None | 2025-03-12 | 2025-03-23 | 2026-03-23 | - | - | 2025-07-14 |
| RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection | NCT06149494 | Altesa Biosciences, Inc. | user2@example.com | None | 2023-11-20 | 2025-03-30 | 2026-03-30 | - | - | 2025-07-14 |
| Phase 1 Study Into Pharmacokinetics and Food Effect of Vapendavir in Healthy Participants and Participants With COPD | NCT05962645 | Altesa Biosciences, Inc. | user2@example.com | None | 2023-05-19 | 2024-05-02 | 2025-05-02 | - | - | 2025-07-14 |